Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• Cahlon O, Zelefsky MJ, Shippy A et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 330–337 (2008).
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(1), 67–74 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Mamgani A, Van Putten WL, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72(4), 980–988 (2008).
   PubMed Web of Science ®Google Scholar
• Zietman AL, Desilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 294(10), 1233–1239 (2005).
   PubMed Web of Science ®Google Scholar
• Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therpay in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28(7), 1106–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8(6), 475–487 (2007).
   PubMed Web of Science ®Google Scholar
• Lee WR, Bae K, Lawton C et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 109(8), 1506–1512 (2007).
   PubMedGoogle Scholar
• Hurwitz MD, Halabi S, Archer L et al. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 117(24), 5579–5588 (2011).
   PubMedGoogle Scholar
• Sumida I, Shiomi H, Yoshioka Y et al. Optimization of dose distribution for HDR brachytherapy of the prostate using Attraction-Repulsion Model. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 643–649 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshioka Y. Current status and perspectives of brachytherapy for prostate cancer. Int. J. Clin. Oncol. 14(1), 31–36 (2009).
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006–1012 (2009).
   PubMed Web of Science ®Google Scholar
• Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1306–1316 (2005).
   PubMedGoogle Scholar
• Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother. Oncol. 103(2), 217–222 (2012).
   PubMed Web of Science ®Google Scholar
• Duchesne GM, Williams SG, Das R, Tai K H. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother. Oncol. 84(2), 128–134 (2007).
   PubMed Web of Science ®Google Scholar
• Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am. J. Clin. Oncol. 32(4), 342–347 (2009).
   PubMedGoogle Scholar
• Galalae RM, Martinez A, Nuernberg N et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther. Onkol. 182(3), 135–141 (2006).
   PubMed Web of Science ®Google Scholar
• Kalkner KM, Wahlgren T, Ryberg M et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol. 46(7), 909–917 (2007).
   PubMed Web of Science ®Google Scholar
• Tang JI, Williams SG, Tai KH, Dean J, Duchesne GM. A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy? Brachytherapy. 5(4), 256–261 (2006).
   PubMedGoogle Scholar
• Galalae RM, Loch T, Riemer B et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther. Onkol. 180(9), 582–589 (2004).
   PubMed Web of Science ®Google Scholar
• Vargas CE, Martinez AA, Boike TP et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 416–423 (2006).
   PubMed Web of Science ®Google Scholar
• Martinez A, Gonzalez J, Spencer W et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J. Urol. 169(3), 974–979; discussion 979–980 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am. J. Clin. Oncol. 33(5), 481–488 (2010).
   PubMed Web of Science ®Google Scholar
• Myers MA, Hagan M P, Todor D et al. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate. Brachytherapy. 11(4), 292–298 (2012).
   PubMedGoogle Scholar
• Martinez-Monge R, Moreno M, Ciervide R et al. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int. J. Radiat. Oncol. Biol. Phys. 82(3), e469–e476 (2012).
   PubMed Web of Science ®Google Scholar
• Kestin LL, Martinez AA, Stromberg JS et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J. Clin. Oncol. 18(15), 2869–2880 (2000).
   PubMedGoogle Scholar
• Hsu IC, Bae K, Shinohara K et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int. J. Radiat. Oncol. Biol. Phys. 78(3), 751–758 (2010).
   PubMed Web of Science ®Google Scholar
• Morton G, Loblaw A, Cheung P et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother. Oncol. 100(3), 463–467 (2011).
   PubMed Web of Science ®Google Scholar
• Borghede G, Hedelin H, Holmang S et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother. Oncol. 44(3), 237–244 (1997).
   PubMedGoogle Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 50(4), 1021–1031 (2001).
   PubMed Web of Science ®Google Scholar
• Wang JZ, Li X A. Impact of tumor repopulation on radiotherapy planning. Int. J. Radiat. Oncol. Biol. Phys. 61(1), 220–227 (2005).
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 56(4), 1093–1104 (2003).
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour E P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52(1), 6–13 (2002).
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat. Rev., (2013).
   Google Scholar
• Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den RB. Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care? Cancer Treat. Rev. 39(3), 212–218 (2013).
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Suzuki O, Kobayashi K et al. External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification. Strahlenther. Onkol. 185(7), 446–452 (2009).
   PubMed Web of Science ®Google Scholar
• Kovacs G, Potter R, Loch T et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother. Oncol. 74(2), 137–148 (2005).
   PubMedGoogle Scholar
• Pisansky TM, Gold DG, Furutani KM et al. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin. Proc. 83(12), 1364–1372 (2008).
   PubMedGoogle Scholar
• Holly R, Morton GC, Sankreacha R et al. Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachytherapy. 10(4), 299–305 (2011).
   PubMed Web of Science ®Google Scholar
• Whitaker M, Hruby G, Lovett A, Patanjali N. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother. Oncol. 101(3), 490–494 (2011).
   PubMed Web of Science ®Google Scholar
• Kovalchuk N, Furutani KM, Macdonald OK, Pisansky TM. Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy. Brachytherapy. 11(2), 111–118 (2012).
   PubMed Web of Science ®Google Scholar
• Herrmann MK, Kertesz T, Gsanger T et al. Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study. Radiat. Oncol. 7, 24 (2012).
   PubMedGoogle Scholar
• Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J. Gen. Intern. Med. 15(10), 694–701 (2000).
   PubMed Web of Science ®Google Scholar
• Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin. Oncol. (R. Coll. Radiol.). 17(4), 219–227 (2005).
   PubMed Web of Science ®Google Scholar
• Hurwitz MD. Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer. Nat. Clin. Pract. Oncol. 5(11), 668–676 (2008).
   PubMedGoogle Scholar
• Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? Expert Rev. Anticancer Ther. 13, in press (2013).
   Google Scholar
• Hinnen KA, Battermann JJ, Van Roermund JG et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 76(5), 1433–1438 (2010).
   PubMed Web of Science ®Google Scholar
• Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J. Urol. 179(5 Suppl), S20–S24 (2008).
   PubMed Web of Science ®Google Scholar
• Stone NN, Stock R G, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int. J. Radiat. Oncol. Biol. Phys. 76(2), 355–360 (2010).
   PubMedGoogle Scholar
• TairaAV, Merrick GS, Galbreath RW, Wallner KE, Butler WM. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 76(2), 349–354 (2010).
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Kuban DA, Levy LB et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 327–333 (2007).
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Yamada Y, Cohen GN et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 65–70 (2007).
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250–1261 (2008).
   PubMed Web of Science ®Google Scholar
• Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 69(2), 338–342 (2007).
   PubMed Web of Science ®Google Scholar
• Keyes M, Miller S, Moravan V et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int. J. Radiat. Oncol. Biol. Phys. 75(3), 649–655 (2009).
   PubMed Web of Science ®Google Scholar
• Zelefsky M, Wallner L, Ling C et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol. 17(2), 517–522 (1999).
   PubMed Web of Science ®Google Scholar
• Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 45(1), 59–67 (1999).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Rogers L, Demanes DJ et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 11(1), 20–32 (2012).
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Li T, Devarajan K, Horwitz EM, Buyyounouski M K. Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method. Cancer. 118(22), 5535–5543 (2012).
   PubMed Web of Science ®Google Scholar
• Abramowitz MC, Li T, Buyyounouski MK et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 112(1), 55–60 (2008).
   PubMedGoogle Scholar
• Buyyounouski MK, Hanlon AL, Eisenberg DF et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1455–1462 (2005).
   PubMedGoogle Scholar
• Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int. J. Radiat. Oncol. Biol. Phys. 57(1), 11–18 (2003).
   PubMed Web of Science ®Google Scholar
• Kleinmann N, Zaorsky NG, Showalter TN, Gomella LG, Lallas CD, Trabulsi E J. The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nature Reviews Urology. 9(5), 258–265 (2012).
   PubMed Web of Science ®Google Scholar
• Luo HL, Fang FM, Kang CH, Chuang YC, Chiang P H. Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate? Int. Urol. Nephrol. 45(1), 113–119 (2013).
   PubMedGoogle Scholar
• Akimoto T, Katoh H, Kitamoto Y et al. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 364–370 (2006).
   PubMedGoogle Scholar
• Khor R, Duchesne G, Tai KH et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85(3), 679–685 (2013).
   PubMed Web of Science ®Google Scholar
• Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar J L. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy. 9(1), 27–35 (2010).
   PubMed Web of Science ®Google Scholar
• Demanes DJ, Martinez AA, Ghilezan M et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(5), 1286–1292 (2011).
   PubMed Web of Science ®Google Scholar
• Song C W. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res. 44(10 Suppl), 4721s–4730s (1984).
   PubMed Web of Science ®Google Scholar
• Eddy H A. Alterations in tumor microvasculature during hyperthermia. Radiology. 137(2), 515–521 (1980).
   PubMed Web of Science ®Google Scholar
• Maluta S, Dall'oglio S, Nadalini L. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia. Int. J. Hyperthermia. 26(8), 765–774 (2010).
   PubMed Web of Science ®Google Scholar
• Hurwitz M. The crossroads of prostate cancer and thermal medicine. Int. J. Hyperthermia. 26(8), 735–736 (2010).
   PubMed Web of Science ®Google Scholar
• Hurwitz MD, Hansen JL, Prokopios-Davos S et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer. 117(3), 510–516 (2011).
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw AA, Raaymakers BW et al. Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU Int. 93(1), 36–41 (2004).
   PubMed Web of Science ®Google Scholar
• Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 109 Suppl 1, 22–29 (2012).
   PubMedGoogle Scholar
• Zietman A, Goitein M, Tepper J E. Technology evolution: is it survival of the fittest? J. Clin. Oncol. 28(27), 4275–4279 (2010).
   PubMedGoogle Scholar
• Shen X, Zaorsky NG, Mishra MV et al. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncol. 8(1), 37–54 (2012).
   PubMed Web of Science ®Google Scholar